Airflow limitation in patients with heart failure: Prevalence and associated factors.

Limitación al flujo aéreo en pacientes con insuficiencia cardíaca: prevalencia y factores asociados.

Journal

Medicina clinica
ISSN: 1578-8989
Titre abrégé: Med Clin (Barc)
Pays: Spain
ID NLM: 0376377

Informations de publication

Date de publication:
13 09 2019
Historique:
received: 15 08 2018
revised: 26 10 2018
accepted: 08 11 2018
pubmed: 9 1 2019
medline: 18 9 2020
entrez: 9 1 2019
Statut: ppublish

Résumé

Chronic obstructive pulmonary disease and heart failure (HF) are 2 diseases with high morbidity and mortality. The coexistence of these two diseases is estimated to be frequent, but has been poorly studied. To study the prevalence of airflow limitation in a sample of patients diagnosed with HF in follow-up in an HF unit and to assess their characteristics and comorbidities. This is a prospective observational study. The patients who visited the HF Unit of the Hospital Universitari Germans Trias i Pujol between January 2014 and June 2015 were included consecutively. Respiratory functional tests were performed and clinical data were obtained. 118 patients were included in the study (age 67.2 years, 77.1% men). The prevalence of non-reversible airflow obstruction was 36.4%, with an underdiagnosis percentage of 67.4%. Patients with airflow limitation had an increase in comorbidities, but no worse prognosis. The prevalence of airflow limitation in patients with HF is high, with a significant degree of underdiagnosis. It seems reasonable to recommend performing a screening spirometry in these patients.

Sections du résumé

BACKGROUND
Chronic obstructive pulmonary disease and heart failure (HF) are 2 diseases with high morbidity and mortality. The coexistence of these two diseases is estimated to be frequent, but has been poorly studied.
AIM
To study the prevalence of airflow limitation in a sample of patients diagnosed with HF in follow-up in an HF unit and to assess their characteristics and comorbidities.
METHODS
This is a prospective observational study. The patients who visited the HF Unit of the Hospital Universitari Germans Trias i Pujol between January 2014 and June 2015 were included consecutively. Respiratory functional tests were performed and clinical data were obtained.
RESULTS
118 patients were included in the study (age 67.2 years, 77.1% men). The prevalence of non-reversible airflow obstruction was 36.4%, with an underdiagnosis percentage of 67.4%. Patients with airflow limitation had an increase in comorbidities, but no worse prognosis.
CONCLUSION
The prevalence of airflow limitation in patients with HF is high, with a significant degree of underdiagnosis. It seems reasonable to recommend performing a screening spirometry in these patients.

Identifiants

pubmed: 30616915
pii: S0025-7753(18)30744-9
doi: 10.1016/j.medcli.2018.11.016
pii:
doi:

Substances chimiques

Biomarkers 0
Peptide Fragments 0
pro-brain natriuretic peptide (1-76) 0
Natriuretic Peptide, Brain 114471-18-0

Types de publication

Journal Article Observational Study

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

191-195

Informations de copyright

Copyright © 2018 Elsevier España, S.L.U. All rights reserved.

Auteurs

Aida Muñoz-Ferrer (A)

Servicio de Neumología, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España; Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Barcelona, España; Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, España.

Laura Rodriguez-Pons (L)

Servicio de Neumología, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España; Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Barcelona, España; Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, España. Electronic address: laurarodriguezpons@gmail.com.

Ignasi Garcia-Olivé (I)

Servicio de Neumología, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España; Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Barcelona, España; CibeRes - Ciber de Enfermedades Respiratorias, Bunyola, Mallorca, España.

Josep Lupón (J)

Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, España; Unitat d'Insuficiència Cardíaca, Servei de Cardiologia, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España; CIBER Cardiovascular, Instituto de Salud Carlos III, Madrid, España.

Marta de Antonio (M)

Unitat d'Insuficiència Cardíaca, Servei de Cardiologia, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España; CIBER Cardiovascular, Instituto de Salud Carlos III, Madrid, España.

Mar Domingo (M)

Unitat d'Insuficiència Cardíaca, Servei de Cardiologia, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España.

Pedro Moliner (P)

Unitat d'Insuficiència Cardíaca, Servei de Cardiologia, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España.

Elisabet Zamora (E)

Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, España; Unitat d'Insuficiència Cardíaca, Servei de Cardiologia, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España; CIBER Cardiovascular, Instituto de Salud Carlos III, Madrid, España.

Evelyn Santiago (E)

Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Barcelona, España; Unitat d'Insuficiència Cardíaca, Servei de Cardiologia, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España.

Antoni Bayes-Genis (A)

Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, España; Unitat d'Insuficiència Cardíaca, Servei de Cardiologia, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España; CIBER Cardiovascular, Instituto de Salud Carlos III, Madrid, España.

Jorge Abad (J)

Servicio de Neumología, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España; Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Barcelona, España; Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, España; CibeRes - Ciber de Enfermedades Respiratorias, Bunyola, Mallorca, España.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH